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ORIGINAL ARTICLE
Fresh whole blood use by forward surgical teams in Afghanistan
is associated with improved survival compared to component
therapy without platelets
Shawn C. Nessen, Brian J. Eastridge, Daniel Cronk, Robert M. Craig, Olle Berséus, Richard Ellison,
Kyle Remick, Jason Seery, Avani Shah, and Philip C. Spinella
INTRODUCTION
BACKGROUND: In Afghanistan, a substantial portion of
resuscitative combat surgery is performed by US Army
forward surgical teams (FSTs). Red blood cells (RBCs)
and fresh frozen plasma (FFP) are available at these
facilities, but platelets are not. FST personnel frequently
encounter high-acuity patient scenarios without the
ability to transfuse platelets. An analysis of the use of
fresh whole blood (FWB) at FSTs therefore allows for an
evaluation of outcomes associated with this practice.
STUDY DESIGN AND METHODS: A retrospective
analysis was performed in prospectively collected data
from all transfused patients at six FSTs from December
2005 to December 2010. Univariate analysis was performed, followed by two separate propensity score
analyses. In-hospital mortality was predicted with the
use of a conditional logistic regression model that incorporated these propensity scores. Subset analysis
included evaluation of patients who received uncrossmatched Type O FWB compared with those who
received type-specific FWB.
RESULTS: A total of 488 patients received a blood
transfusion. There were no significant differences in age,
sex, or Glasgow Coma Scale in those who received or
did not receive FWB. Injury Severity Scores were higher
in patients transfused FWB. In our adjusted analyses,
patients who received RBCs and FFP with FWB had
improved survival compared with those who received
RBCs and FFP without FWB. Of 94 FWB recipients, 46
FWB recipients (49%) were given uncrossmatched Type
O FWB, while 48 recipients (51%) received type-specific
FWB. There was no significant difference in mortality
between patients that received uncrossmatched Type O
and type-specific FWB.
CONCLUSIONS: The use of FWB in austere combat
environments appears to be safe and is independently
associated with improved survival to discharge when
compared with resuscitation with RBCs and FFP alone.
Mortality was similar for patients transfused
uncrossmatched Type O compared with ABO typespecific FWB in an austere setting.

This article is a U.S. government work, and is not subject to copyright in the United States.

With the end of combat operations in Iraq, attention to
Afghanistan has returned. There, a substantial portion of
resuscitative surgery has been performed by 20 personnel
US Army forward surgical teams (FSTs) or similar units.
Many of these teams have been split to more widely disseminate surgical care platforms.1 FSTs doctrinally carry
only 20 units of red blood cells (RBCs), but currently in
Afghanistan they are augmented with fresh frozen plasma
(FFP) and some with cryoprecipitate. Platelets (PLTs) are
not available.1-4 The concept of damage control resuscitation with the use of RBCs, FFP, and PLTs in balanced ratios
that approximate those of whole blood has been supported by several recent publications in the military and
civilian trauma literature.5-11 Although these studies are
retrospective in nature, the military has adopted a clinical
practice guideline recommending 1:1:1 unit ratios of these
blood components. In addition, current theater clinical
practice guidelines recommend the use of fresh whole
blood (FWB) be reserved for “casualties who are anticipated to require massive transfusion (10 or more units of
packed RBCs in 24 hr), for those with clinically significant
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shock or coagulopathy (e.g., bleeding with associated
metabolic acidosis, thrombocytopenia, or international
normalized ratio >1.5) when optimal component therapy
(e.g., apheresis PLTs and FFP) is unavailable or stored
component therapy is not adequately resuscitating a
patient with immediately life-threatening injuries.”12 Due
to the austerity of their environment, FST personnel frequently encounter high-acuity patient scenarios without
the ability to transfuse PLTs. The use of FWB in these locations therefore generates an opportunity to evaluate outcomes associated with whole blood transfusions. Current
US military doctrine states that FWB must be type specific
when transfused. In some remote settings where donors
are limited, this is not possible, and uncrossmatched Type
O FWB is transfused as a last resort. The objective of this
study is to examine the association of FWB use versus
use of component therapy (RBCs and FFP) only, with
in-hospital mortality in combat casualties admitted to
FSTs. Furthermore, we examine the association between
receipts of ABO type-specific FWB versus uncrossmatched Type O FWB on in-hospital mortality.

METHODS
The Institutional Review Board of the US Army Medical
Research and Materiel Command approved the retrospective analysis of all admission performance improvement data of a convenience sample of six FSTs from
December 2005 to December 2010. These units were
chosen because they developed a comprehensive performance improvement plan that included collection of
data regarding blood transfusion. The data were prospectively collected by the individual FST units during the
5-year study period. Blood product utilization, mechanism of injury, type of injuries, number and type of surgical procedures performed, and ultimate patient
outcome were recorded. Demographic data including
patient status, sex, and age were also collected. Physiologic variables including temperature, systolic blood
pressure (SBP), respiratory rate, and Glasgow Coma Scale
(GCS) at the time of initial patient presentation were collected. Mechanism of injury was also collected and categorized into four broad areas: gunshot wound, blast
injury, motor vehicle crash, and burn. An Abbreviated
Injury Score and Injury Severity Score (ISS) were calculated for each transfused patient with the use of the Military Abbreviated Injury Score 2005 (revised 2007). The
primary endpoint was mortality determined at inpatient
discharge from a Level V military facility for US forces or
discharge to a local national facility for Afghanis. Other
data collected included the number of blood products
transfused, activated recombinant factor VIIa (rFVIIa)
usage, patient age, and temperature on presentation.
Patients determined to have died within 1 hour of presentation were eliminated from the study in an attempt
108S
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to mitigate survivor bias. Afghani patients with penetrating head injuries with initial GCS of ⱕ7 were eliminated
as they were often treated expectantly. Statistical analysis
was performed by an independent statistician. Univariate analysis was performed with the use of SAS 9.1 (SAS
Institute, Inc., Cary, NC). Two separate propensity score
analyses were performed utilizing STATA 11.2 (StataCorp
LP, College Station, TX). Variables that were associated
with the use of FWB in the univariate analysis were used
to calculate propensity scores. SBP at arrival to FST,
arrival temperature, use of rFVIIa, total RBCs, and total
FFP administered were used to calculate the propensity
score that was the probability of receiving FWB. The balancing property of the propensity scores was tested and
propensity scores were determined to be balanced in the
FWB and non-FWB groups. The propensity scores were
used in the logistic regression model predicting death,
adjusting for the ISSs and the Glasgow Coma Scores. The
propensity score was included as a continuous variable
in the first model. In the second analysis, propensity
scores were used to create strata or groups. Subjects were
grouped into six strata based on similarity of propensity
score and therefore have similar risk profile, without
regard to outcome or receipt of FWB. Following stratification, death in each group was predicted with the use of
a conditional logistic regression. Conditional logistic
regression approach combines within-stratum effects
with between-stratum effects to estimate the overall FWB
effect on death.

RESULTS
A total of 488 patients met inclusion criteria. They received
2612 units of RBCs, 1566 units of FFP, and 416 units of
FWB. A total of 394 patients received blood transfusion
without receiving FWB and 94 patients received blood
transfusions that included FWB. Table 1 indicates that
ISSs and respiratory rate were significantly higher in
patients receiving FWB, while arrival SBP and temperature
were significantly lower. There was no significant difference in age, sex, or GCS in those who received or did not
receive FWB.
Predictably, patients receiving FWB also required significantly more units of RBCs and FFP. These patients also
were more likely to receive rFVIIa and massive blood
transfusion (MBT) defined as 10 or more units of RBCs or
the equivalent combination of RBCs and FWB in the first
24 hours (Table 2). There was no statistical difference in
in-hospital mortality between study groups. In patients
who received FWB, the unadjusted mortality rate was
5.3% (5/94) for those transfused FWB and 8.8% (35/394)
for patients who did not receive FWB. Mechanism of
injury was similar between patients who received component therapy with FWB and those who received only RBCs
and FFP (Table 3).

FRESH WHOLE BLOOD USE BY SURGICAL TEAMS

TABLE 1. Admission vital sign and laboratory data by fresh whole blood (FWB) use
Age (years)
US and/or coalition
Non-US and/or coalition
Male sex
GCS
ISS
Arrival SBP (mmHg)
Arrival RR
Arrival temperature (°C)

No FWB (n = 394)
25.6 ⫾ 11.5; 25 (20, 30); 371
53 (13.5)
341 (86.5)
375 (95.2)
13.8 ⫾ 2.7; 15 (14, 15); 394
19.6 ⫾ 9.3; 16.5 (16, 25); 394
110.5 ⫾ 27.1; 110 (95, 128); 388
22 ⫾ 8.2; 21 (16, 26); 383
36.4 ⫾ 0.8; 36.6 (36.2, 37.0); 373

FWB (n = 94)
28.1 ⫾ 9.7; 25 (22, 30); 81
14 (14.9)
80 (85.1)
90 (95.7)
13.2 ⫾ 3.4; 15 (14, 15); 93
22.4 ⫾ 8.9; 20 (16, 26); 94
99.9 ⫾ 30.1; 97 (80, 123); 94
25.2 ⫾ 9.7; 25 (18, 30); 94
36.1 ⫾ 1.2; 36.2 (35.6, 36.8); 83

p Value
0.08
0.715
0.715
1.00
0.11
0.008
<0.001
0.005
0.005

Continuous variables reported as mean ⫾ SD; median (LowerQ, UpperQ); n.
Categorical variables reported as n (%).
GCS = Glasgow Coma Scale; ISS = Injury Severity Score; RR = respiratory rate; SBP = systolic blood pressure; SD = standard deviation.

increased mortality (Table 7). A subset
analysis was performed for patients who
No FWB (n = 394)
FWB (n = 94)
p Value
only received MBT. Ninety-four patients
FWB (U)
0
4.4 ⫾ 4; 3 (2,6)
<0.001
received MBT, with 49 transfused FWB,
Total RBCs (U)
4.7 ⫾ 3.7; 4 (2, 6)
12.7 ⫾ 9.4; 10 (6, 16)
<0.001
RBCs, and FFP and 45 patients received
Total plasma (U)
2.6 ⫾ 2.7; 2 (0, 4)
10 ⫾ 7.1; 8 (5, 12)
<0.001
only RBCs and FFP. The mortality rate in
Total blood products (U)
7.3 ⫾ 5.8; 6 (3, 10)
18.3 ⫾ 13.1; 14 (10, 24)
<0.001
Factor VII given
23 (5.8)
24 (25.5)
<0.001
those patients who received MBT with
Massive transfusion
46 (11.6)
49 (52.1)
<0.001
RBCs, FFP, and FWB was 8.16% and those
Continuous variables reported as mean ⫾ SD; median (LowerQ, UpperQ).
who received MBT with RBCs and
Categorical variables reported as n (%).
FFP alone had a mortality of 26.67%
RBCs = red blood cells; SD = standard deviation.
(p = 0.025). Another subset analysis was
performed in patients who received
FWB (n = 94) according to receipt of ABO
TABLE 3. Univariate comparison of mechanism of injury
type-specific FWB (51%) or uncrossVariable
FWB (n = 94)
No FWB (n = 394)
p Value
matched Type O FWB (49%). There was
Gunshot wound
48.9%
46.7%
0.696
no statistical difference in in-hospital
Blast
43.6%
46.7%
0.590
mortality for patients who received
Burns
0%
1.3%
0.272
type-specific FWB (6.1%) compared with
Motor vehicle collision
0%
3.0%
0.087
Other
6.4%
3.0%
0.123
those who received uncrossmatched
FWB = fresh whole blood.
Type O FWB (6.7%) with three deaths in
each group. Data were not available to
report the ABO type of recipients who
received uncrossmatched Type O FWB. No transfusion
Lower GCS, higher ISS, lower arrival SBP, and lower
reactions were noted in patients who received FWB.
arrival patient temperature were associated with death
(Table 4). Also, higher total RBC transfusion and higher
total blood product transfusion were associated with
DISCUSSION
death. Interestingly, total FFP and FWB transfused were not
associated with death. Consistent with previous reports,
This is the first study to compare transfusion of RBCs and
patient mortality was associated with MBT and rFVIIa use
FFP with FWB to patients who received only RBCs and FFP
(Table 5). Two separate propensity score analyses were
at Level II or forward surgical facilities. Our results indiperformed with the use of a continuous variable and then
cate that, in a far forward setting during military operastratification method. With the use of continuous variable
tions, transfusion of RBCs, FFP, and FWB is independently
logistic regression analysis, patients who received RBCs
associated with improved in-hospital survival compared
and FFP with FWB had significantly improved survival
with RBCs and FFP alone. As a result, not only does it
compared with those who received RBCs and FFP without
appear to be safe to transfuse FWB in this setting when
FWB, odds ratio (OR) (95% confidence interval [CI]) 0.096
PLTs are not available but it may also improve outcomes
(0.02-0.53). Higher ISS and lower GCS were associated with
compared with the use of RBCs and FFP alone.
increased mortality (Table 6). With the use of a stratified
The coagulopathy associated with hemorrhaging
propensity score analysis, FWB use was also associated
trauma patients has been long recognized.13,14 In Vietnam,
with improved survival OR (95% CI), 0.11 (0.02-0.78).
this clinical manifestation was sometimes referred to as
Higher ISS and lower GCS were also associated with
oozing syndrome, tomato juice syndrome, and red ink
TABLE 2. Blood products use by fresh whole blood (FWB)
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TABLE 4. Admission vitals, patient demographics, and laboratory data by death status
Alive (n = 448)
25.9 ⫾ 11; 25 (20, 30); 417
426 (95.1)
64 (14.3)
384 (85.7)
14.1 ⫾ 2.3; 15 (14, 15); 447
19.4 ⫾ 8.6; 16 (16, 25); 448
109.9 ⫾ 26.8; 110 (93, 128); 443
22.5 ⫾ 8.4; 22 (16, 28); 438
36.4 ⫾ 0.9; 36.6 (36.1, 37.0); 420

Age (years)
Male sex
US and/or coalition
Non-US and/or coalition
GCS
ISS
Arrival SBP (mmHg)
Arrival RR
Arrival temp (°C)

Dead (n = 40)
28.3 ⫾ 13.5; 25 (21, 31); 35
39 (97.5)
3 (7.5)
37 (92.5)
9.4 ⫾ 4.7; 9.5 (5.5, 15); 40
28. ⫾ 12.1; 25 (19, 32); 40
91.3 ⫾ 35; 84 (78, 109); 39
24.1 ⫾ 11; 24 (17, 32); 39
35.8 ⫾ 1.1; 35.8 (35.3, 36.4); 36

p Value
0.23
0.71
0.232
0.232
<0.001
<0.001
0.002
0.41
<0.001

Continuous variables reported as mean ⫾ SD; median (LowerQ, UpperQ); n.
Categorical variables reported as n (%).
GCS = Glasgow Coma Scale; ISS = Injury Severity Score; RR = respiratory rate; SBP = systolic blood pressure; SD = standard deviation.

TABLE 5. Blood products use by death status
Alive (n = 448)
89 (19.9)
0.8 ⫾ 2.2; 0 (0, 0); 448
5.8 ⫾ 5.5; 4 (2, 8); 448
3.9 ⫾ 4.5; 3 (0, 6); 448
8.9 ⫾ 8; 7 (3, 12); 448
39 (8.7)
79 (17.6)

FWB patient status
FWB (U)
Total RBCs (U)
Total plasma (U)
Total blood products (U)
Factor VII given
Massive transfusion

Dead (n = 40)
5 (12.5)
1.4 ⫾ 4.7; 0 (0, 0); 40
10.5 ⫾ 10.4; 8 (4, 13); 40
6.1 ⫾ 7.9; 4 (1.5, 6); 40
15.1 ⫾ 14.2; 10 (6, 19) 42
8 (20)
16 (40)

p Value
0.250
0.43
0.008
0.09
0.01
0.04
0.002

Continuous variables reported as mean ⫾ SD; median (LowerQ, UpperQ); n.
Categorical variables reported as n (%).
FWB = fresh whole blood; RBCs = red blood cells; SD = standard deviation.

TABLE 6. Propensity score used as continuous
variable in logistic regression predicting effect
of FWB on death
FWB use
Injury Severity Score
Glasgow Coma Score
Propensity score

Odds ratio
0.096
1.07
0.72
9.72

95% CI
0.02,0.53
1.03,1.11
0.65,0.79
1.45,64.97

p Value
0.008
<0.001
<0.001
0.019

Arrival systolic blood pressure, arrival temperature, use of factor
VIIa, total red blood cells, and total plasma administered were
used to calculate propensity score.
CI = confidence interval; FWB = fresh whole blood.

TABLE 7. Stratified propensity score analysis
predicting the effect of the use of FWB on death
FWB use
Injury Severity Score
Glasgow Coma Score

Odds ratio
0.11
1.06
0.71

95% CI
0.02, 0.78
1.01, 1.11
0.63, 0.79

p Value
0.03
0.01
<0.001

CI = confidence interval; FWB = fresh whole blood.

syndrome.15 This coagulopathic bleeding is associated
with the lethal triad of trauma, which also includes acidosis and hypothermia. However, coagulopathy is also recognized to occur early in trauma patients and is
exacerbated by blood loss, acidosis, hypothermia, con110S
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sumption, fibrinolysis, and dilution.9,10,16-20 As many as
one-third of combat trauma patients who require transfusion are coagulopathic at their initial presentation to a
surgical facility.14
Recognizing the frequent futility of correcting coagulopathy and shock secondary to severe nonsurgical bleeding
with traditional resuscitative methods after it occurs, the
concept of hemostatic or damage control resuscitation
with all the components of whole blood has evolved. The
initial military research effort evaluated FFP transfused
concurrent with RBCs and which ratio of RBC:FFP was
associated with increased survival.5,20,21 The conclusions of
these studies were that transfusion of FFP concurrently
with RBCs in patients requiring large volumes of blood was
associated with improved survival and the RBC:FFP recommended ratio was 1:1. As a result of these studies, damage
control resuscitation with the use of a 1:1 ratio of RBC and
FFP was adopted by all surgical units including FSTs and
combat support hospitals (CSHs) in Iraq and Afghanistan.
This was relatively easily done as FFP can be frozen and
stored for up to 1 year and was already available in both
theaters. PLTs were not available in theater until late 2004
and then only at the larger combat support hospitals.3
Largely due to the sporadic and inconsistent availability of RBCs and FFP early in the war, FWB was frequently
used as a source of RBCs, FFP, and PLTs. Anecdotal reports
suggested that FWB was an excellent resuscitation fluid

FRESH WHOLE BLOOD USE BY SURGICAL TEAMS

and an early retrospective study by Spinella and colleagues
suggested that FWB combined with RBCs and FFP may be
superior to traditional component therapy consisting of
RBCs, FFP, and apheresis PLTs.23 However, a subsequent
retrospective review by Perkins and colleagues compared
MBT patients who received either apheresis PLTs or FWB
and found that adjusted survival approached significance
(p = 0.06) at 24 hours with no difference at 30 days, and a
higher unadjusted incidence of ARDS in the FWB group
was noted.22 Based largely on these studies, a theater practice guideline was published, which recommended the use
of FWB for circumstances when PLTs were not available.
However, when component therapy provided inadequate
resuscitation, the clinical practice guideline supported the
use of FWB at the discretion of the surgeon.23
Afghanistan is a mature theater and apheresis PLTs
are now available at CSHs, also referred to by North Atlantic Treaty Organization (NATO) forces as Role III facilities.2
However, in Afghanistan, FSTs provide initial surgery to
the combat injured in the majority of locations. The FST
was designed to provide a surgical capability to a maneuvering combat brigade and the ability to do this successfully has been well reported in the literature.24-28 In an
attempt to provide surgical capability to as many locations
as possible the 20 personnel FSTs have been split. This
practice although initially questioned has been shown to
be successful with excellent outcomes achieved by appropriately trained teams.1,28 PLTs are not available at either
full or split FSTs. This is problematic as the main purpose
of the FST is to provide damage control surgery and resuscitation. Under these circumstances, FWB is commonly
used due to its PLT constituent and almost always in conjunction with RBCs and FFP. There are additional theoretical benefits of FWB compared with components, which
include fresh RBCs that may have increased efficacy at
delivering oxygen as well as reduced harmful storage
lesion effects. In addition, FWB is a more concentrated
product (less anticoagulants and additives) than whole
blood reconstituted from stored components.
Of the 488 patients in this study who received blood
transfusion, 94 received FWB (19.26%). Patients who
received FWB on average received 4.43 units of FWB, 8.27
units of RBCs, 5.59 units of FFP, and a mean of 18.27 units
of total blood products. This shows that in large part
patients who received FWB received it in the context of
large volume if not MBT resuscitation.
In this study, patients transfused before the fall of
2008 usually received uncrossmatched Type O. It is likely
that many of the patients who received Type O blood in
this setting were Type O patients. During this period, in
the forward setting, where there was no capacity to
perform ABO typing of donors, it was not possible to
determine how many casualties who received transfusion
uncrossmatched Type O blood received Type ABO-specific
blood. After this time, the theater policy mandated only

transfusing type-specific FWB, and FSTs were augmented
with type and cross capability. This study showed no difference in mortality between patients receiving uncrossmatched FWB compared with when type-specific FWB
was intentionally transfused. The safety of transfusing
uncrossmatched or Type O FWB in dire circumstances
when type-specific FWB cannot be provided requires
further study. The current US military policy prohibiting
this practice may be increasing the risk of mortality for
patients unnecessarily. No data exist that the authors are
aware of that indicate that the use of Type O FWB as a last
resort when ABO type-specific blood is not available is
associated with increased risk of poor outcomes. While no
transfusion reactions were noted in FWB recipients, the
signs and symptoms of a transfusion reaction can easily
be missed during massive hemorrhage and MBT. The
additive risk introduced by the transfusion of Type O
blood with incompatible plasma ABO antibodies is a
severe intravascular hemolytic transfusion reaction
(IHTR). In contrast to other transfusion reactions, IHTR
constitutes an acute clinically recognizable entity characterized by physical discomfort, chest and/or abdominal
pain, fever, hypotension, dyspnea, and appearance at the
beginning of the transfusion. Depending on the transfused volume, later symptoms may include macroscopic
hematuria, disseminated intravascular coagulation, and
circulatory failure. In spite of the wide use of Type O whole
blood during World War II, no reports of IHTR were
observed until 1944 when a few were reported.29 The reactions were not fatal but led to a US policy of screening the
Type O donors for ABO plasma antibodies and excluding
those with high titers from serving as “universal donors.”30
During the later Korean and Vietnam Wars, 52,000 and
230,300 transfusions were reported without any IHTR
caused by a compatible transfusion. There were however
some IHTRs as a result of incompatible blood transfusions
due to administrative errors.31
Until very recently, there was no doctrinal capability
to type and crossmatched blood at an FST and the complexity of managing a blood bank capable of typing and
crossmatching blood was beyond the reasonable expectations of these small teams, especially in the early days of
combat operations.4,32 This practice is currently prohibited by the current US Army FWB clinical practice guideline in favor of type and crossmatched blood, despite no
data indicating that the practice is associated with worse
outcomes.1,4,35-37
Our study has limitations inherent to retrospective
analyses. A convenience sample may introduce sampling
bias. More importantly, our results may be affected by survival bias as it takes a mean of 30-45 minutes to receive the
first unit of FWB. In this study, we eliminated patients who
died within the first hour of treatment at the FST, which
minimizes survival bias. The majority of those who died
did so after transfer; however, due to the transfer of
Volume 53, January 2013 Supplement
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Afghani patients to local facilities, determining the cause
of death was not always possible, which makes it difficult
to draw any conclusions on the long-term effects of FWB
transfusion.

CONCLUSIONS

resuscitation: identifying blood ratios associated with
improved survival. J Trauma 2008;65:527-34.
9. Hess JR, Holcomb JB, Hoyt DB. Damage control
resuscitation: the need for specific blood products to
treat the coagulopathy of trauma. Transfusion 2006;46:
685-6.
10. Holcomb JB, Jenkins D, Rhee P, Johannigman J, Mahoney

The use of FWB in austere combat environments appears
to be safe and is independently associated with improved
survival when compared with resuscitation with RBCs and
FFP alone. Mortality was similar for patients transfused
uncrossmatched Type O FWB compared with ABO typespecific FWB in an austere setting. Further studies evaluating outcomes related to the use of uncrossmatched Type
O FWB in these settings are warranted.
CONFLICT OF INTEREST
The opinions or assertions contained herein are the private views
of the author and are not to be construed as official or as reflecting the views of the US Department of the Army or the US Department of Defense.

REFERENCES
1. Nessen SC, Cronk DR, Edens J, Eastridge BJ, Little TR,
Windsor J, Blackbourne LH, Holcomb JB. US Army twosurgeon teams operating in remote Afghanistan—an evaluation of split-based forward surgical team operations.
J Trauma 2009;66:S37-47.
2. The Borden Institute. Levels of medical care. In: The
Borden Institute, editor. Emergency war surgery. Washington, DC: Borden Institute at Walter Reed Army Medical
Center; 2004. p. 2.2-.3.
3. Spinella P, Dunne J, Bielman G, O’Connell RJ, Borgman
MA, Cap AP, Rentas F. Constant challenges and evolution

4.

5.

6.

7.

8.

of US military transfusion medicine and blood operations
in combat. Transfusion 2012;52:1146-53.
Kauvar DS, Holcomb JB, Norris GC, Hess JR. Fresh whole
blood transfusion: a controversial military practice.
J Trauma 2006;61:181-4.
Borgman MA, Spinella PC, Perkins JG, Grathwohl KW,
Repine T, Beekley AC, Sebesta J, Jenkins D, Wade CE,
Holcomb JB. The ratio of blood products transfused affects
mortality in patients receiving massive transfusions at a
combat support hospital. J Trauma 2007;63:805-13.
Duchesne JC, Hunt JP, Wahl G, Marr AB, Wang YZ, Weintraub SE, Wright MJ, McSwain NE Jr. Review of current
blood transfusion strategies in a mature level I trauma
center: were we wrong for the last 60 years? J Trauma 2008;
65:272-6.
Ho AM, Karmakar MK, Dion PW. Are we giving enough
coagulation factors during major trauma resuscitation? Am
J Surg 2005;190:479-84.
Gunter OL Jr, Au BK, Isbell JM, Mowery NT, Young PP,
Cotton BA. Optimizing outcomes in damage control

112S

TRANSFUSION Volume 53, January 2013 Supplement

P, Mehta S, Cox ED, Gehrke MJ, Beilman GJ, Schreiber M,
Flaherty SF, Grathwohl KW, Spinella PC, Perkins JG,
Beekley AC, McMullin NR, Park MS, Gonzalez EA, Wade
CE, Dubick MA, Schwab CW, Moore FA, Champion HR,
Hoyt DB, Hess JR. Damage control resuscitation: directly
addressing the early coagulopathy of trauma. J Trauma
2007;62:307-10.
11. Beekley AC. Damage control resuscitation: a sensible
approach to the exsanguinating surgical patient. Crit Care
Med 2008;36:S267-74.
12. Research USAIoS. Joint trauma system clinical practice
guidelines [monograph on the internet]. 2012. [cited 2012
Nov 28]. Available from: URL: http://www.usaisr.amedd.
army.mil/clinical_practice_guidelines.html
13. Brohi K, Singh J, Heron M, Coats T. Acute traumatic coagulopathy. J Trauma 2003;54:1127-30.
14. Hess JR, Brohi K, Dutton RP, Hauser CJ, Holcomb JB,
Kluger Y, Mackway-Jones K, Parr MJ, Rizoli SB, Yukioka T,
Hoyt DB, Bouillon B. The coagulopathy of trauma: a review
of mechanisms. J Trauma 2008;65:748-54.
15. Neel S, Major General. The military blood program. In:
Medical support of the U.S. Army in Vietnam 1965-1970.
Chapter 9. 1991. [cited 2012 Jun 30]. Available from: URL:
http://history.amedd.army.mil/booksdocs/vietnam/
medicalsupport/default.html
16. Sarah E, Niles SE, McLaughlin DF, Perkins JG, Wade CE, Li
Y, Spinella PC, Holcomb JB. Increased mortality associated
with the early coagulopathy of trauma in combat casualties. J Trauma 2008;64:1459-65.
17. Schlag G, Redl H. Mediators in trauma. Acta Anaesthesiol
Belg 1987;38:281-91.
18. Hess JR. Blood and coagulation support in trauma care.
Hematology 2007;1:187.
19. McMullin NR, Holcomb JB, Sondeen JL. Hemostatic resuscitation. In: Vincent JL, editor. Yearbook of intensive care
and emergency medicine 2006. Heidelberg, Germany:
Springer-Verlag; 2006. p. 265-78.
20. Brohi K, Cohen MJ, Ganter MT, Matthaway MA, Mackersie
RC, Pittet JF. Acute traumatic coagulopathy: initiated by
hypoperfusion modulated through the protein C pathway?
Ann Surg 2007;245:812-18.
21. Gonzalez EA, Moore FA, Holcomb JB, Miller CC, Kozar RA,
Todd SR, Cocanour CS, Balldin BC, McKinley BA. Fresh
frozen plasma should be given earlier to patients requiring
massive transfusion. J Trauma 2007;62:112-19.
22. Spinella PC, Perkins JG, Grathwol KW, Beekley AC, Niles
SE, McLaughlin DF, Wade CE, Holcomb JB. Effect of
plasma and red blood cell transfusion on survival in

FRESH WHOLE BLOOD USE BY SURGICAL TEAMS

patients with combat related traumatic injuries. J Trauma
2008;64:S69-78.
23. Spinella PC, Perkins JG, Grathwohl KW, Beekley AC,
Holcomb JB. Warm fresh whole blood is independently
associated with improved survival for patients with
combat-related traumatic injuries. J Trauma 2009;66:S6976.
24. Perkins JG, Cap AP, Spinella PC, Shorr AF, Beekley AC,
Grathwohl KW, Rentas FJ, Wade CE, Holcomb JB; 31st
Combat Support Hospital Research Group. Comparison of
platelet transfusion as fresh whole blood versus apheresis
platelets for massively transfused combat trauma patients.
Transfusion 2011;51:242-52.
25. US Army Institute of Surgical Research. Fresh whole blood
transfusion. Updated Oct 2012. [cited 2012 Nov 28]. Available from: URL: http://www.usaisr.amedd.army.mil/assets/
cpgs/Fresh_Whole_Blood_Transfusion_24_Oct_12.pdf
26. Rush RM Jr, Stockmaster NR, Stinger HK, Arrington ED,
Devine JG, Atteberry L, Starnes BW, Place RJ. Supporting
the Global War on Terror: a tale of two campaigns featuring
the 250th Forward Surgical Team (Airborne). Am J Surg
2005;189:564-70. discussion 570.
27. Beekley AC, Watts DM. Combat trauma experience with
the United States Army 102nd Forward Surgical Team in
Afghanistan. Am J Surg 2004;187:652-4.
28. Beekley AC, Starnes BW, Sebesta JA. Lessons learned from
modern military surgery. Surg Clin North Am 2007;87:15784. vii.
29. Beekley AC. United States military surgical response to
modern large-scale conflicts: the ongoing evolution of a
trauma system. Surg Clin North Am 2006;86:689-709.

30. Eastridge BJ, Stansbury LJ, Stinger H, Blackbourne L,
Holcomb JB. Forward surgical teams provide comparable
outcomes to combat support hospitals during support and
stabilization operations on the battlefield. J Trauma 2009;
66:S48-50.
31. Ebert RV, Emerson CP. A clinical study of transfusion
reactions: the hemolytic effect of group-O blood and
pooled plasma containing incompatible isoagglutinins.
J Clin Invest 1946;25:627-38.
32. Barnes A Jr. Status of use of universal donor blood transfusion. Crit Rev Clin Lab Sci 1973;4:147-60.
33. Berséus O, Boman K, Nessen SC, Westerberg LA. Risks of
hemolysis due to anti-A and anti-B caused by the
transfusion of blood or blood components containing
ABO-incompatible plasma. Transfusion 2013;53(Suppl.
1):114S-123S.
34. Spinella PC, Strandenes G, Rein EB, Seghatchian J, Hervig
T. Symposium on fresh whole blood for severe traumatic
shock: from in-hospital to far forward resuscitation. Transfus Apher Sci 2012;46:113-17.
35. Hess JR. Blood use in war and disaster: the U.S.
experience. Scand J Trauma Resusc Emerg Med 2005;13:7481.
36. Repine TB, Perkins JG, Kauvar DS, Blackborne L. The use
of fresh whole blood in massive transfusion. J Trauma
2006;60:S59-69.
37. Mabry RL, Holcomb JB, Baker AM, Cloonan CC, Uhorchak
JM, Perkins DE, Canfield AJ, Hagmann JH. United States
Army rangers in Somalia: an analysis of combat casualties
on an urban battlefield. J Trauma 2000;49:515-28; discussion 528-9.

Volume 53, January 2013 Supplement

TRANSFUSION

113S

